Valuing clinical strategies early in development

A cost analysis of allogeneic peripheral blood stem cell transplantation

C. L. Bennett, Teresa Waters, T. J. Stinson, O. Almagor, Z. S. Pavletic, S. R. Tarantolo, M. R. Bishop

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Allogeneic peripheral blood stem cell transplantation (alloPBSCT) is an emerging technology. As this technology develops, transplant centers are concerned with looking for technologic advances that will result in improvements in clinical outcomes and lower costs. We provide comparative estimates of costs and resource use for alloPBSCT in comparison to allogeneic bone marrow transplantation (alloBMT) for persons with hematologic malignancies from the time of harvest to 100 days post transplant. A retrospective, cost-identification analysis was conducted for patients in two consecutive phase II clinical trials at the University of Nebraska Medical Center. Identical preparative regimens, graft-versus-host disease prophylaxis, post-transplant hematopoietic colony-stimulating factor treatment regimens, and discharge criteria were used. Total median costs were $18,304 lower for alloPBSCT, with lower costs during recovery; specifically for hospitalization, platelet products, hematopoietic growth factors, intravenous hyperalimentation, supportive care agents, supplies, and antibacterial agents. This study provides preliminary evidence for short-term cost savings associated with alloPBSCT. However, concerns exist over the potential for higher costs due to preliminary reports of higher rates of chronic graft-versus-host disease, as well as more intensive induction regimens that may result in lower relapse rates. The premature adoption of new technologies based on short-term economic factors, in the absence of adequate clinical trial data, may prove to be ill-advised, particularly for complex medical treatments such as allogeneic transplantation.

Original languageEnglish (US)
Pages (from-to)555-560
Number of pages6
JournalBone Marrow Transplantation
Volume24
Issue number5
DOIs
StatePublished - Jan 1 1999

Fingerprint

Peripheral Blood Stem Cell Transplantation
Costs and Cost Analysis
Homologous Transplantation
Graft vs Host Disease
Technology
Transplants
Colony-Stimulating Factors
Phase II Clinical Trials
Total Parenteral Nutrition
Cost Savings
Hematologic Neoplasms
Bone Marrow Transplantation
Intercellular Signaling Peptides and Proteins
Hospitalization
Blood Platelets
Economics
Clinical Trials
Anti-Bacterial Agents
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Valuing clinical strategies early in development : A cost analysis of allogeneic peripheral blood stem cell transplantation. / Bennett, C. L.; Waters, Teresa; Stinson, T. J.; Almagor, O.; Pavletic, Z. S.; Tarantolo, S. R.; Bishop, M. R.

In: Bone Marrow Transplantation, Vol. 24, No. 5, 01.01.1999, p. 555-560.

Research output: Contribution to journalArticle

Bennett, C. L. ; Waters, Teresa ; Stinson, T. J. ; Almagor, O. ; Pavletic, Z. S. ; Tarantolo, S. R. ; Bishop, M. R. / Valuing clinical strategies early in development : A cost analysis of allogeneic peripheral blood stem cell transplantation. In: Bone Marrow Transplantation. 1999 ; Vol. 24, No. 5. pp. 555-560.
@article{80f9cbefec6048aaaef627ffdee5cb40,
title = "Valuing clinical strategies early in development: A cost analysis of allogeneic peripheral blood stem cell transplantation",
abstract = "Allogeneic peripheral blood stem cell transplantation (alloPBSCT) is an emerging technology. As this technology develops, transplant centers are concerned with looking for technologic advances that will result in improvements in clinical outcomes and lower costs. We provide comparative estimates of costs and resource use for alloPBSCT in comparison to allogeneic bone marrow transplantation (alloBMT) for persons with hematologic malignancies from the time of harvest to 100 days post transplant. A retrospective, cost-identification analysis was conducted for patients in two consecutive phase II clinical trials at the University of Nebraska Medical Center. Identical preparative regimens, graft-versus-host disease prophylaxis, post-transplant hematopoietic colony-stimulating factor treatment regimens, and discharge criteria were used. Total median costs were $18,304 lower for alloPBSCT, with lower costs during recovery; specifically for hospitalization, platelet products, hematopoietic growth factors, intravenous hyperalimentation, supportive care agents, supplies, and antibacterial agents. This study provides preliminary evidence for short-term cost savings associated with alloPBSCT. However, concerns exist over the potential for higher costs due to preliminary reports of higher rates of chronic graft-versus-host disease, as well as more intensive induction regimens that may result in lower relapse rates. The premature adoption of new technologies based on short-term economic factors, in the absence of adequate clinical trial data, may prove to be ill-advised, particularly for complex medical treatments such as allogeneic transplantation.",
author = "Bennett, {C. L.} and Teresa Waters and Stinson, {T. J.} and O. Almagor and Pavletic, {Z. S.} and Tarantolo, {S. R.} and Bishop, {M. R.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701945",
language = "English (US)",
volume = "24",
pages = "555--560",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Valuing clinical strategies early in development

T2 - A cost analysis of allogeneic peripheral blood stem cell transplantation

AU - Bennett, C. L.

AU - Waters, Teresa

AU - Stinson, T. J.

AU - Almagor, O.

AU - Pavletic, Z. S.

AU - Tarantolo, S. R.

AU - Bishop, M. R.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Allogeneic peripheral blood stem cell transplantation (alloPBSCT) is an emerging technology. As this technology develops, transplant centers are concerned with looking for technologic advances that will result in improvements in clinical outcomes and lower costs. We provide comparative estimates of costs and resource use for alloPBSCT in comparison to allogeneic bone marrow transplantation (alloBMT) for persons with hematologic malignancies from the time of harvest to 100 days post transplant. A retrospective, cost-identification analysis was conducted for patients in two consecutive phase II clinical trials at the University of Nebraska Medical Center. Identical preparative regimens, graft-versus-host disease prophylaxis, post-transplant hematopoietic colony-stimulating factor treatment regimens, and discharge criteria were used. Total median costs were $18,304 lower for alloPBSCT, with lower costs during recovery; specifically for hospitalization, platelet products, hematopoietic growth factors, intravenous hyperalimentation, supportive care agents, supplies, and antibacterial agents. This study provides preliminary evidence for short-term cost savings associated with alloPBSCT. However, concerns exist over the potential for higher costs due to preliminary reports of higher rates of chronic graft-versus-host disease, as well as more intensive induction regimens that may result in lower relapse rates. The premature adoption of new technologies based on short-term economic factors, in the absence of adequate clinical trial data, may prove to be ill-advised, particularly for complex medical treatments such as allogeneic transplantation.

AB - Allogeneic peripheral blood stem cell transplantation (alloPBSCT) is an emerging technology. As this technology develops, transplant centers are concerned with looking for technologic advances that will result in improvements in clinical outcomes and lower costs. We provide comparative estimates of costs and resource use for alloPBSCT in comparison to allogeneic bone marrow transplantation (alloBMT) for persons with hematologic malignancies from the time of harvest to 100 days post transplant. A retrospective, cost-identification analysis was conducted for patients in two consecutive phase II clinical trials at the University of Nebraska Medical Center. Identical preparative regimens, graft-versus-host disease prophylaxis, post-transplant hematopoietic colony-stimulating factor treatment regimens, and discharge criteria were used. Total median costs were $18,304 lower for alloPBSCT, with lower costs during recovery; specifically for hospitalization, platelet products, hematopoietic growth factors, intravenous hyperalimentation, supportive care agents, supplies, and antibacterial agents. This study provides preliminary evidence for short-term cost savings associated with alloPBSCT. However, concerns exist over the potential for higher costs due to preliminary reports of higher rates of chronic graft-versus-host disease, as well as more intensive induction regimens that may result in lower relapse rates. The premature adoption of new technologies based on short-term economic factors, in the absence of adequate clinical trial data, may prove to be ill-advised, particularly for complex medical treatments such as allogeneic transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0032877607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032877607&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701945

DO - 10.1038/sj.bmt.1701945

M3 - Article

VL - 24

SP - 555

EP - 560

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -